![]() |
|
|
![]() Inspired by Nature, with Science as our Tool, we create Unique Healthcare Products.ProFibrix leverages its expertise in fibrinogen technology to develop and market innovative products for the hemostasis and regenerative medicine markets. Human fibrinogen plays a pivotal role in blood clotting and tissue healing. ProFibrix is led by a team with extensive commercial, clinical and scientific experience in the field of hemostasis. Fibrocaps™, the company’s lead product, which is based on a mixture of fibrinogen and thrombin, is a unique dry powder topical tissue sealant that stops acute and severe bleeding during surgery or after trauma injury. Fibrocaps has major advantages over existing liquid tissue sealants: it is ready-to-use, is stable at room-temperature, and can be applied in different formats, including in sprays or bandages. |
ProFibrix News
Press Release
ProFibrix obtains government loan of up to EUR 5 million (~US$7.4 million)LEIDEN, THE NETHERLANDS and SEATTLE, WA, January 7, 2010 - more>Press Release
ProFibrix raises US $11 million (EUR 8 million) in series B financing LEIDEN, THE NETHERLANDS and SEATTLE, WA, August 24, 2009 - more>Press ReleaseProFibrix initiates Phase II clinical trial of its lead topical hemostat product Fibrocaps™SEATTLE, WA, and LEIDEN, THE NETHERLANDS, June 18, 2009 - more>Press ReleaseProFibrix Steps Up Recombinant Fibrinogen Program with PER.C6® License from CrucellCommercial License to Accelerate Development of New Hemostasis Breakthrough Products more>Press ReleaseProFibrix expands Management team and opens US subsidiaryNew COO brings financing and product development experience in the US. more> ProFibrix raises up to $ 11 million (€ 8.5 million) Series A financing led by Index VenturesLeiden, The Netherlands, 26 March2007. ProFibrix B.V., a Dutch biotech company focused on products to stop
bleeding and initiate tissue repair, today announced that it has
closed a Series A financing raising $ 11 Million. more> |
|
![]() |
![]() |
![]() |